Trial Profile

A phase 2 double-blind, placebo-controlled, crossover-controlled study will compare different bolus and constant infusion dosing regimens of DMT in healthy control participants and individuals with depression

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 31 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

31 Oct 2022 New trial record
24 Oct 2022 According to an Algernon Pharmaceuticals media release, Professor Deepak Cyril D'Souza, is the principal investigator of this study.
24 Oct 2022 According to an Algernon Pharmaceuticals media release, the company has entered an Investigator-Initiated Clinical Trial Agreement (CTA) with Yale University for the investigation of multiple intravenous doses of DMT for the treatment of depression.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com